Literature DB >> 15031633

Diversity of PR3-ANCA epitope specificity in Wegener's granulomatosis. Analysis using the biosensor technology.

Agnieszka A Rarok1, Ymke M van der Geld, Coen A Stegeman, Pieter C Limburg, Cees G M Kallenberg.   

Abstract

Wegener's granulomatosis is a systemic disease characterized by the presence of antineutrophil cytoplasm autoantibodies specific for proteinase 3 (PR3-ANCA). The functional characteristics of PR3-ANCA differ between quiescent and active disease, suggesting changes in the properties of the autoantibodies in time. Using biosensor technology, we found that PR3-ANCA of different patients (n = 8) recognize a limited number of overlapping regions on PR3 at the time of diagnosis of Wegener's granulomatosis. This area might cover an immunodominant epitope, common for PR3-ANCA from all patients, irrespective of the size of the total area recognized by an individual autoantibody. Experiments with sera (n = 4) collected at the moment of diagnosis and at the time of relapse showed that the individual epitope specificities of PR3-ANCA change during the course of the disease. These changes in epitope specificity of PR3-ANCA may be responsible for the differences in functional properties of these autoantibodies between various stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15031633     DOI: 10.1023/b:joci.0000010422.73892.b5

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  48 in total

1.  Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3.

Authors:  P Bini; J E Gabay; A Teitel; M Melchior; J L Zhou; K B Elkon
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

Review 2.  Anti-cytoplasmic antibodies in Wegener's granulomatosis are directed against proteinase 3.

Authors:  J Lüdemann; B Utecht; W L Gross
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

Review 3.  B-cell epitope spreading in autoimmunity.

Authors:  J A James; J B Harley
Journal:  Immunol Rev       Date:  1998-08       Impact factor: 12.988

4.  Epitope mapping by surface plasmon resonance in the BIAcore.

Authors:  B Johne
Journal:  Mol Biotechnol       Date:  1998-02       Impact factor: 2.695

5.  Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies.

Authors:  M A Audrain; T A Baranger; N Moguilevski; S J Martin; A Devys; C M Lockwood; J Y Muller; V L Esnault
Journal:  Clin Exp Immunol       Date:  1997-01       Impact factor: 4.330

6.  In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG).

Authors:  Y M van der Geld; M G Huitema; C F Franssen; R van der Zee; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  2000-12       Impact factor: 4.330

7.  Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils.

Authors:  R Kettritz; J C Jennette; R J Falk
Journal:  J Am Soc Nephrol       Date:  1997-03       Impact factor: 10.121

8.  Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A).

Authors:  F Topfer; T Gordon; J McCluskey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-31       Impact factor: 11.205

9.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils.

Authors:  R Goldschmeding; C E van der Schoot; D ten Bokkel Huinink; C E Hack; M E van den Ende; C G Kallenberg; A E von dem Borne
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

10.  Subcellular localization and heterogeneity of neutral proteases in neutrophilic polymorphonuclear leukocytes.

Authors:  B Dewald; R Rindler-Ludwig; U Bretz; M Baggiolini
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N.

Authors:  Peter Hewins; Frances Belmonte; J Charles Jennette; Ronald J Falk; Gloria A Preston
Journal:  Autoimmunity       Date:  2010-08-16       Impact factor: 2.815

Review 3.  B cell epitope specificity in ANCA-associated vasculitis: does it matter?

Authors:  Y M van der Geld; C A Stegeman; C G M Kallenberg
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

4.  Epitope shift of proteinase-3 anti-neutrophil cytoplasmic antibodies in patients with small vessel vasculitis.

Authors:  D Selga; M Segelmark; L Gunnarsson; T Hellmark
Journal:  Clin Exp Immunol       Date:  2010-01-06       Impact factor: 4.330

Review 5.  Detection of autoantibodies in a point-of-care rheumatology setting.

Authors:  Konstantin N Konstantinov; Antonios Tzamaloukas; Robert L Rubin
Journal:  Auto Immun Highlights       Date:  2013-05-18

Review 6.  Biosensors in clinical chemistry - 2011 update.

Authors:  Paul D'Orazio
Journal:  Clin Chim Acta       Date:  2011-06-26       Impact factor: 3.786

Review 7.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

8.  4C3 Human Monoclonal Antibody: A Proof of Concept for Non-pathogenic Proteinase 3 Anti-neutrophil Cytoplasmic Antibodies in Granulomatosis With Polyangiitis.

Authors:  Jérôme Granel; Roxane Lemoine; Eric Morello; Yann Gallais; Julie Mariot; Marion Drapeau; Astrid Musnier; Anne Poupon; Martine Pugnière; Seda Seren; Dalila Nouar; Valérie Gouilleux-Gruart; Hervé Watier; Brice Korkmaz; Cyrille Hoarau
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.